QNTM Stock Risk & Deep Value Analysis

Quantum Biopharma Ltd

DVR Score

2.1

out of 10

Risk Trap

What You Need to Know About QNTM Stock

We analyzed Quantum Biopharma Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran QNTM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Mar 25, 2026•Run Fresh Analysis →

QNTM Risk Analysis & Red Flags

What Could Go Wrong

The company operates with virtually no financial transparency and likely has limited cash reserves. If 'unbuzzd' faces unexpected regulatory hurdles, fails to achieve commercialization, or Quantum Biopharma cannot secure substantial additional funding, the company could face severe financial distress, including bankruptcy or significant shareholder dilution, leading to a near-total loss for investors.

Risk Matrix

Overall

Aggressive

Financial

High

Market

Medium

Competitive

High

Execution

High

Regulatory

High

Red Flags

⚠
Extreme lack of comprehensive financial reporting (no recent 10-K/Q filings, balance sheet, or cash flow data).
⚠
Reliance on a single early-stage product ('unbuzzd') with unproven commercial viability.
⚠
Only one analyst covers the stock, indicating very limited institutional interest or validation.
⚠
Current stock price ($2.24) is near its 52-week low ($2.07) after reaching a high of $38.25, suggesting prior hype and significant sell-off.

Upcoming Risk Events

📅
Negative earnings surprise or lack of material updates on 2026-03-27
📅
Failure to secure additional funding or significant share dilution
📅
Regulatory setbacks or rejection for 'unbuzzd' product
📅
Emergence of direct competitors with similar or superior products

When to Reconsider

🚪
Failure to report earnings or provide material updates on 'unbuzzd' on 2026-03-27.
🚪
Official rejection of 'unbuzzd' by regulatory bodies or significant delays.
🚪
Announced capital raise resulting in excessive share dilution (e.g., >30%).
🚪
Stock drops and sustains below $1.50 per share.

Unlock QNTM Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Quantum Biopharma Ltd. represents a highly speculative, high-reward bet on the successful development and commercialization of its 'unbuzzd' product. Recent peer-reviewed trial results suggest a potential breakthrough in alcohol metabolism, offering a path to significant market disruption. While the lack of financial transparency creates extreme risk, the potential for 'unbuzzd' to achieve regulatory approval and market adoption could drive a multi-bagger return for risk-tolerant investors willing to accept the possibility of total capital loss.

Is QNTM Stock Undervalued?

Quantum Biopharma Ltd. (QNTM) presents an extremely high-risk, speculative opportunity. While the company was previously categorized as defunct, recent real-time intelligence reveals a material change: a peer-reviewed publication of its 'unbuzzd' trial, showing positive results (40% faster BAC reduction, increased alertness) and triggering significant stock momentum. This indicates an active business operation and a potential product catalyst, moving it beyond a 'dud' status. A single analyst with a highly optimistic $35.50 price target also points to perceived speculative upside. However, the company suffers from critical financial opacity, with no available recent earnings reports, balance sheet, cash flow, or profitability data, making fundamental valuation impossible. Leadership track record and broader competitive advantages are unknown. The profound lack of transparency and established business operations positions QNTM as an extremely speculative bet, primarily on the success of 'unbuzzd', with a high potential for total loss alongside potential for extreme gains.

Unlock the full AI analysis for QNTM

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

QNTM Price Targets & Strategy

12-Month Target

$15.00

Bull Case

$35.50

Bear Case

$0.50

Valuation Basis

Highly speculative, based on implied commercial potential of 'unbuzzd' discounted for extreme early stage, lack of financials, and single analyst coverage (upside) vs. potential for complete business failure (downside).

Entry Strategy

Given extreme volatility and low transparency, dollar-cost average between current price ($2.24, per market intelligence) and $2.00 (near 52-week low) for aggressive, highly speculative positions.

Exit Strategy

Take 50% profit at $10.00, remaining at $15.00-$20.00. Implement a stop-loss at $1.50 to limit downside exposure.

Portfolio Allocation

0.5% for aggressive risk tolerance only, as a highly speculative 'moonshot' position.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is QNTM Financially Healthy?

Valuation

P/E Ratio

-0.41

Price/Book

20.90

Profitability

Return on Equity

-238.45%

Balance Sheet

Current Ratio

1.41

Quick Ratio

0.67

Debt/Equity

0.30

Cash Flow

EBITDA

-$18.39M

Other

Beta (Volatility)

1.60

Does QNTM Have a Competitive Moat?

Moat Rating

⚪ None

Moat Trend

Emerging

Moat Sources

1 Identified

Intangible Assets/IP (potential for patent protection for 'unbuzzd')

Highly fragile; depends entirely on successful patenting, regulatory approval, and ability to commercialize 'unbuzzd' rapidly before competitors develop similar products or formulations. Currently, no durable moat exists.

Moat Erosion Risks

•Failure to obtain strong patent protection for 'unbuzzd' or similar products.
•Rapid market entry by competitors with similar or superior products.
•Regulatory rejection or significant delays for 'unbuzzd' approval.
•'Unbuzzd' not proving to be sufficiently differentiated or effective in real-world scenarios.

QNTM Competitive Moat Analysis

QNTM Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Speculative Bullish, primarily driven by the 'unbuzzd' trial publication, but with awareness of high risk.

Institutional Sentiment

Neutral, evidenced by a single analyst's Buy rating and high price target, but a complete absence of reported institutional ownership or widespread coverage.

Insider Activity (Form 4)

No Form 4 filings reported in the last 90 days, indicating no recent insider buying or selling.

Options Flow

Normal options activity, with no specific unusual institutional positioning reported.

Earnings Intelligence

Next Earnings

2026-03-27

Surprise Probability

High

Historical Earnings Pattern

No historical earnings data or reaction patterns are available due to the lack of prior financial reports.

Key Metrics to Watch

Any update on 'unbuzzd' commercialization timeline or regulatory progressCash position and burn rateAny reported revenue or detailed expense breakdownForward guidance or outlook beyond 'unbuzzd'

Competitive Position

Top Competitor

N/A

Market Share Trend

Unknown, as 'unbuzzd' is in early stages of development and commercialization has not begun.

Valuation vs Peers

Cannot assess due to a complete lack of fundamental valuation metrics (P/E, EV/EBITDA, P/S) and identifiable direct publicly traded peers for its specialized 'unbuzzd' product.

Competitive Advantages

•Potential first-mover advantage with the 'unbuzzd' product, validated by peer-reviewed trial publication.
•Proprietary technology/formulation if 'unbuzzd' is patent-protected (unconfirmed).

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive QNTM Stock Higher?

Near-Term (0-6 months)

•Q4 2025/Fiscal Q1 2026 Earnings Report (expected 2026-03-27)
•Further updates on 'unbuzzd' regulatory pathway and commercialization strategy

Medium-Term (6-18 months)

•Potential regulatory approval for 'unbuzzd'
•Initial commercial launch and sales data for 'unbuzzd'
•Formation of strategic partnerships for distribution or further R&D

Long-Term (18+ months)

•Significant market adoption and share gain for 'unbuzzd'
•Expansion of biopharma pipeline beyond 'unbuzzd'

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for QNTM?

✓
Positive updates on 'unbuzzd' regulatory filings or trial phases (e.g., Phase 3 results)
✓
Announcement of institutional funding rounds or strategic distribution partnerships
✓
Any initiation of transparent financial reporting (10-K/Q) showing revenue or a path to profitability

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Quantum Biopharma Ltd (QNTM)?

As of March 25, 2026, Quantum Biopharma Ltd has a DVR Score of 2.1 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Quantum Biopharma Ltd?

Quantum Biopharma Ltd's market capitalization is approximately $16.1M..

What is the risk level for QNTM stock?

Our analysis rates Quantum Biopharma Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of QNTM?

Quantum Biopharma Ltd currently has a price-to-earnings (P/E) ratio of -0.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is Quantum Biopharma Ltd's revenue growing?

Quantum Biopharma Ltd has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.

Is QNTM stock profitable?

Quantum Biopharma Ltd has a profit margin of 0.0%. The company is currently unprofitable.

How often is the QNTM DVR analysis updated?

Our AI-powered analysis of Quantum Biopharma Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for QNTM (Quantum Biopharma Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.